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Prevention and management of Clostridium difficile infection (CDI) can be improved by rapid and reliable diagnostics. The Vi-
das C. difficile glutamate dehydrogenase assay had performance comparable to that of the Quik Chek-60 assay (overall agree-
ment, 95%) and a sensitivity of>93%; thus, it is suitable as the first test in two-stage algorithms for a CDI diagnosis.
Accurate and timely diagnosis of Clostridium difficile infection(CDI) is a key step in optimizing patient management and
reducing cross-infection risk, and diagnosis has historically relied
on the detection of C. difficile toxins in fecal samples (1). An alter-
native target,C. difficile-specific glutamate dehydrogenase (GDH),
first identified in 1991 by Lyerly et al., has been shown to be
highly conserved between PCR ribotypes of C. difficile (2, 3).
Current United Kingdom and European guidance recommends
GDH as a possible first assay in a two-stage diagnostic algorithm
for CDI, most commonly alongside toxin detection (1, 4, 5). The
poor prognostic value of current C. difficile toxin enzyme immu-
noassays (EIA) means that they should not be used as standalone
assays for the diagnosis of CDI (6–8).
We prospectively tested fecal samples routinely submitted for
C. difficile testing between July 2012 and January 2013 to labora-
tories in one United Kingdom hospital (Leeds Teaching Hospital
NHS Trust, Leeds, United Kingdom) and two U.S. hospitals
(Wishard Health Services, Indianapolis, IN, USA, and Tricore
Reference Laboratory, Albuquerque, NM, USA). Samples in-
cluded were 3 days old and had been refrigerated to follow the
international good practices for C. difficile diagnosis. All samples,
once made anonymous, were tested at the receiving laboratory
using a new enzyme-linked fluorescence assay (ELFA), the Vidas
C. difficile GDH assay (bioMérieux, France), a comparator GDH
EIA, Quik Chek-60 (Techlab, USA), and two culture methods.
Samples were frozen at70°C before shipping to Leeds for testing
with an in-house PCR assay for the GDH gene gluD. Samples used
in this service evaluationwere residual diagnosticmaterial and did
not require ethical approval or consent in theUnited Kingdom. In
the United States, approval of the ethics committee (institutional
review board) was granted, while the requirement for informed
consent was waived.
Fecal samples were directly inoculated onto C. difficile chro-
mID culture media (bioMeriéux, France). In addition, fecal sam-
ples were alcohol shocked in 50% alcohol before inoculation on to
cycloserine-cefoxitine fructose agar (CCFA) (Remel, USA). All
plates were incubated at 37°C in an anaerobic environment for 24
h (chromID) or 48 h (CCFA) before inspection for suspect colo-
nies (according to the manufacturers’ instructions). The identity
was confirmedwith aMicrogen latex agglutination kit (Microgen,
UnitedKingdom) for theUnitedKingdom site or withGram stain
and Prodisc kits (Remel, USA) for U.S. sites. Both commercial
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TABLE 1 Sequence of primers and probes used in GDH (gluD) PCR assaya
Oligonucleotide name Sequence 5= modificationb 3= modificationc
Yersi F1 GGAGGAAGGGTTAAGTGTTA
Yersi R1 GAGTTAGCCGGTGCTTCTT
Yersi P1 GCGAGTAACGTCAATGTTCAGTGC Cy5 BHQ2
gluD F3 GTCTTGGATGGTTGATGAGTAC
gluD R2 TTCCTAATTTAGCAGCAGCTTC
gluD P1 AAGCCAGTTGAATTTGGTGG FAM BHQ1
a Shown are the sequences of primer and probes, and their modifications, that were used in the GDH PCR assay at Leeds. Yersi primers and probes and gluD primers were described
previously (9, 10), and the gluD probe was designed in house (Leeds).
b Cy5, cyanine 5; FAM, 6-carboxyfluorescein.
c BHQ, black hole quencher.
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immunoassays were performed as per themanufacturers’ instruc-
tions.
In-house PCR specific for C. difficile gluD was performed at
Leeds on samples that had been frozen at70°C, either at Leeds or
before transportation from the other sites. Briefly, samples were
defrosted and then diluted 1/10 in 1ml STAR buffer (Roche, Ger-
many) with the addition of 1/10 chloroform before being spun at
16,000 g for 10min in a centrifuge. An internal control (Yersinia
ruckeri) was added to each sample before DNA was extracted on
the QiaXtractor using the DX kit (Qiagen Ltd., United Kingdom).
Template DNAwas added to the Brilliant QPCRmultiplexmaster
mix (Agilent,UnitedKingdom) alongwith primers andprobes for
gluD and Yersi (Table 1). Amplification was performed on a Strat-
agene MX3000P (Agilent, United Kingdom) using the following
thermocycling conditions: 95°C for 10 min followed by 45 cycles
at 95°C for 30 s, 60°C for 30 s, and 72°C for 30 s. A previous
evaluation determined that a gluD cycle time value of35 cycles
indicated a positive PCR result (data not shown).
In total, 1,914 samples were tested during the study; 1,906 had
complete data for all the assays and were used for comparisons.
Over half of the samples (53.1%) came from patients aged 60
years (Table 2), with slightly more women than men (ratio, 1.42
females:1 male). Liquid feces made up 62% of the total samples
tested across all three sites (Table 2); only one site (Tricore) tested
formed fecal samples (2.5% of the total).
Of the two reference culture media used, the chromID C. dif-
ficile medium was more sensitive than the Remel CCFA medium
(67.0% versus 62.5%) compared with GDH PCR. The 95% con-
fidence interval (CI) of the difference between the sensitivities of
the assays did not include zero (difference, 4.5%; 95% CI,
7.5% to1.4%), indicating a significant difference between the
sensitivity of the two culture media (11).
The Vidas C. difficile GDH assay was 93.0% sensitive and
91.8% specific compared with chromID C. difficile (Table 3). The
assay was slightly more sensitive compared with Remel CCFA
(95.8%) but, conversely, was less specific (90.0%) (Table 3). The
TABLE 2 Baseline characteristics of patients included in the study
Characteristic
No. (%) of patients at:
All sites Leeds Wishard Tricore
Total 1,914 (100.0) 524 (27.4) 466 (24.3) 924 (48.3)
Age
Child2 yr 3 (0.2) 0 (0.0) 3 (0.6) 0 (0.0)
Child 2–12 yr 79 (4.1) 12 (2.3) 19 (4.1) 48 (5.2)
Adolescent 13–21 yr 58 (3.0) 11 (2.1) 17 (3.6) 30 (3.2)
Adult 22–59 yr 757 (39.6) 149 (28.4) 217 (46.6) 391 (42.3)
Adult60 yr 1,017 (53.1) 352 (67.2) 210 (45.1) 455 (49.2)
Age class
Pediatric (22 yr) 140 (7.3) 23 (4.4) 39 (8.4) 78 (8.4)
Adult (22 yr) 1,774 (92.7) 501 (95.6) 427 (91.6) 846 (91.6)
Gender
Female 1,123 (58.7) 296 (56.5) 267 (57.3) 560 (60.7)
Male 790 (41.3) 228 (43.5) 199 (42.7) 363 (39.3)
Nature of specimen
Formed 47 (2.5) 0 (0.0) 0 (0.0) 47 (5.1)
Liquid 1,186 (62.0) 380 (72.5) 363 (77.9) 443 (47.9)
Semiformed 681 (35.6) 144 (27.5) 103 (22.1) 434 (47.0)
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overall levels of agreement of the Vidas GDH assay with chromID
C. difficile and Remel CCFA were 92% and 91%, respectively.
There was geographical variance in the performance of the assay;
sensitivity was lower at Leeds Teaching Hospitals NHS Trust but
not statistically different from the two U.S. sites, while specificity
was statistically lower at Tricore (data not shown). It should be
noted, however, that neither medium performed as well as the
Vidas C. difficile GDH assay compared with the GDH PCR assay
(Table 4). In a three-way comparison, the 95% CI of the differ-
ences between sensitivities of the assays did not include zero, in-
dicating a significant difference of the sensitivity of the Vidas C.
difficile GDH assay versus both culture media (Table 4) (11). The
sensitivity of the Vidas C. difficile GDH assay did not alter signif-
icantly if the equivocal GDH PCR results were treated as positive,
negative, or void (Table 5). While the Vidas C. difficileGDH assay
had higher sensitivity, it was significantly less specific than both
culture media (Table 4), indicating that this assay may be useful
only as a screening assay (for example, as part of a two-step diag-
nostic algorithm).
In this multicenter comparison study, we found that the Vidas
C. difficileGDHassaywas comparable in performance to the com-
mercially availableGDHEIA (QuikChek-60, Techlab,USA), with
an overall agreement of 95% (Table 6). The Vidas assay has the
advantage of being automated, with good traceability and more
comprehensive quality control than theQuik Chek. It is, however,
slower (40 min run time) and requires a larger sample volume
(200 l versus 25 l).
There are some limitations to our study. We did not use a gold
standard reference method for a CDI diagnosis; however, GDH
alone cannot reliably diagnose CDI and is diagnostic only in con-
junction with a toxin detection assay (6). Culture and PCR for the
gluD gene, therefore, are more representative comparators when
assessing GDH detection assays. This does pose some difficulties
when comparing our results with other publications, as most in-
corporated a reference method for diagnosing CDI. Notably,
however, a meta-analysis showed that, for the three studies that
compared a GDH assay with culture, the sensitivities of the GDH
assays examined were 95.0%, 93.4%, and 93.5%, that is, compa-
rable with the Vidas C. difficile GDH assay studied here (12).
GDH assays have proved to be useful as the first assay of a
two-stage algorithm for CDI diagnosis (4, 5). It is important to
emphasize that the second assay should detect toxins A and B ofC.
difficile, as detection of the toxin has been shown to correlate with
both mortality and severity of infection (6, 13). The Vidas C. dif-
ficile GDH assay is a sensitive method that makes it suitable as a
first assay in these recommended diagnostic algorithms.
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TABLE 5 Effect of analyzing equivocal GDH PCR results as positive,
negative, or void on the performance of the Vidas C. difficile GDH assay
using AUROC analysisa
Equivocal GDH PCR
result
AUROC of Vidas C. difficile
GDH assay compared with
GDH PCR (%) 95% CI
Positive 0.83 0.80–0.86
Negative 0.86 0.83–0.88
Voidb 0.86 0.84–0.89
a AUROC, area under receiver operator curve.
b GDH PCR equivocal results analyzed as void were removed from the analysis.
C. difﬁcile GDH Detection Using the Vidas GDH Assay
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